Most patients with HCC die within one year of diagnosis. No standard therapy exists for advanced HCC. Sorafenib is a multikinase inhibitor with antiangiogenic, proapoptotic and Raf kinase—inhibitory activity. Median time to progression was also longer in sorafenib-treated patients than in those who received placebo 5. The study was considered so successful that it was halted earlier this year and patients in the placebo group were offered sorafenib.
Food and Drug Administration in August. Sorafenib targets both the tumor cell and tumor vasculature. In preclinical studies, sorafenib has been shown to target members of two classes of kinases known to be involved in both cell proliferation growth and angiogenesis blood supply —two important processes that enable cancer growth. J Clin Oncol. Nexavar, which is also being investigated in a wide range of cancers such as breast, lung and ovarian, had first-quarter sales of million euros, up Riociguat promise confirmed Meantime, Bayer has presented previously-released data from a Phase II study on riociguat for the treatment of chronic thromboembolic pulmonary hypertension CTEPH and pulmonary arterial hypertension at the American Thoracic Society meeting in San Diego.
Results from the week, uncontrolled study demonstrated that riociguat significantly improved exercise capacity in a group of 75 patients with CTEPH and PAH. Bayer has begun Phase III studies in both indications and if successful, analysts believe riociguat could be a blockbuster. Free news subscriptions Free RSS feeds. Japanese approvals for Bayer's Nexavar and Sanofi's Clexane.
Get the latest pharma news delivered to your inbox. A valid email address is required.
0コメント